DK200000266A - Farmaceutisk sammensætning indeholdende en opløsning af cyclosporin. - Google Patents

Farmaceutisk sammensætning indeholdende en opløsning af cyclosporin. Download PDF

Info

Publication number
DK200000266A
DK200000266A DK200000266A DKPA200000266A DK200000266A DK 200000266 A DK200000266 A DK 200000266A DK 200000266 A DK200000266 A DK 200000266A DK PA200000266 A DKPA200000266 A DK PA200000266A DK 200000266 A DK200000266 A DK 200000266A
Authority
DK
Denmark
Prior art keywords
solution
cyclosporine
pharmaceutical composition
composition containing
cyclosporin
Prior art date
Application number
DK200000266A
Other languages
English (en)
Inventor
List Martin
Sucker Heinz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6316557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK200000266(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of DK200000266A publication Critical patent/DK200000266A/da
Application granted granted Critical
Publication of DK173345B1 publication Critical patent/DK173345B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

PATENTKRAV: 1. Farmaceutisk sammensætning indeholdende en opløsning af cyclosporin i et med vand blandbart opløsningsmiddel, hvilken sammensætning danner en hydrosol omfattende faste partikler af cyclosporin og en stabilisator for partiklerne ved blanding med vand. 2. Sammensætning ifølge krav 1, kendetegnet ved, at cyclosporinen er cyclosporin A. 3. Sammensætning ifølge krav 1 eller 2, kendetegnet ved, at cyclosporinpartiklerne har en gennemsnitlig statistisk diameter mindre end 500 nanometer. 4. Sammensætning ifølge ehvert af de foregående krav, kendetegnet ved, at hydrosolen er blevet tilsat syre. 5. Sammensætning ifølge krav 4, kendetegnet ved, at syren er citronsyre. 6. Sammensætning ifølge ethvert af de foregående krav, kendetegnet ved, at stabilisatoren indeholder en farmaceutisk acceptabel gelatine. 7. Sammensætning ifølge krav 6, kendetegnet ved, at vægtforholdet mellem cyclosporin og stabilisator ligger fra 1:10 til 1:30.
DK200000266A 1986-12-19 2000-02-21 Farmaceutisk sammensætning indeholdende en opløsning af cyclosporin. DK173345B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3643392 1986-12-19
DE3643392 1986-12-19

Publications (2)

Publication Number Publication Date
DK200000266A true DK200000266A (da) 2000-02-21
DK173345B1 DK173345B1 (da) 2000-08-07

Family

ID=6316557

Family Applications (2)

Application Number Title Priority Date Filing Date
DK198706641A DK173319B1 (da) 1986-12-19 1987-12-17 Hydrosol, dens fremstilling og anvendelse samt oral farmaceutisk sammensætning og dennes anvendelse
DK200000266A DK173345B1 (da) 1986-12-19 2000-02-21 Farmaceutisk sammensætning indeholdende en opløsning af cyclosporin.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK198706641A DK173319B1 (da) 1986-12-19 1987-12-17 Hydrosol, dens fremstilling og anvendelse samt oral farmaceutisk sammensætning og dennes anvendelse

Country Status (25)

Country Link
US (1) US5389382A (da)
JP (1) JP2617958B2 (da)
KR (1) KR960005136B1 (da)
AT (1) AT397914B (da)
BE (1) BE1000848A3 (da)
CA (1) CA1308656C (da)
CH (1) CH679451A5 (da)
DD (1) DD281344A5 (da)
DE (1) DE3742473C2 (da)
DK (2) DK173319B1 (da)
ES (1) ES2028492A6 (da)
FR (1) FR2608427B1 (da)
GB (1) GB2200048B (da)
GR (1) GR871938B (da)
HU (1) HU205861B (da)
IE (1) IE61179B1 (da)
IL (1) IL84855A (da)
IT (1) IT1230118B (da)
LU (1) LU87079A1 (da)
MY (1) MY102037A (da)
NL (1) NL194638C (da)
NZ (1) NZ222964A (da)
PT (1) PT86399B (da)
SE (1) SE503020C2 (da)
ZA (1) ZA879533B (da)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE4140194C2 (de) * 1991-12-05 1998-02-19 Alfatec Pharma Gmbh Ein Dihydropyridinderivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
DE4140191C2 (de) * 1991-12-05 1998-02-19 Alfatec Pharma Gmbh Retardform für ein Indometacin oder Acemetacin enthaltendes Arzneimittel und seine Herstellung
DE4140179C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Ibuprofen enthaltendes Arzneimittel
DE4140185C2 (de) * 1991-12-05 1996-02-01 Alfatec Pharma Gmbh Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
DE4140172C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Retardform für ein Ibuprofen enthaltendes Arzneimittel
DE4140183C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Retardform für ein Flurbiprofen enthaltendes Arzneimittel
AU671965B2 (en) * 1991-12-05 1996-09-19 Alfatec-Pharma Gmbh Pharmaceutically Applicable Nanosol and Process for Preparing The Same
DE4140184C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Flurbiprofen enthaltendes Arzneimittel
DE4140195C2 (de) * 1991-12-05 1994-10-27 Alfatec Pharma Gmbh Pharmazeutisch applizierbares Nanosol und Verfahren zu seiner Herstellung
CZ278863B6 (en) * 1992-09-07 1994-07-13 Galena Medicinal preparations with n-methylated cyclic undecapeptides
KR0146671B1 (ko) * 1994-02-25 1998-08-17 김충환 사이클로스포린-함유 분말 조성물
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
EP1369111A1 (en) * 1996-10-03 2003-12-10 Hermes Biosciences, Inc. Hydrophilic microparticles and methods to prepare same
US6249717B1 (en) * 1996-11-08 2001-06-19 Sangstat Medical Corporation Liquid medication dispenser apparatus
US6187747B1 (en) 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
US6008191A (en) * 1997-09-08 1999-12-28 Panacea Biotec Limited Pharmaceutical compositions containing cyclosporin
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
AU750245B2 (en) 1997-10-08 2002-07-11 Aurinia Phamaceuticals Inc. Deuterated cyclosporine analogs and their use as immunomodulating agents
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
US6447806B1 (en) 1999-02-25 2002-09-10 Novartis Ag Pharmaceutical compositions comprised of stabilized peptide particles
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
DE10040707A1 (de) * 2000-08-17 2002-03-14 Braun Melsungen Ag Kolloidale Pharmakomodulation injizierter Arzneimittel
IL160761A0 (en) * 2001-10-19 2004-08-31 Isotechnika Inc Novel cyclosporin analog microemulsion preconcentrates
MXPA04003625A (es) * 2001-10-19 2004-12-02 Sotechnika Inc Sintesis de analogos de ciclosporina.
DE10205362A1 (de) * 2002-02-08 2003-08-21 Abbott Gmbh & Co Kg Verfahren zur Herstellung wasserdispergierbarer Trockenpulver von in Wasser schwer löslichen Verbindungen
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
US7838034B2 (en) 2002-07-30 2010-11-23 Grunenthal Gmbh Intravenous pharmaceutical form of administration
DE10234784A1 (de) * 2002-07-30 2004-02-19 Günenthal GmbH Intravenös applizierbare, pharmazeutische Darreichungsform
EP1592406A2 (en) * 2003-02-13 2005-11-09 Phares Pharmaceutical Research N.V. Lipophilic compositions
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US7754243B2 (en) * 2004-08-03 2010-07-13 Clemson University Research Foundation Aqueous suspension of nanoscale drug particles from supercritical fluid processing
DE102005011786A1 (de) * 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
DE502006005846D1 (de) * 2005-04-13 2010-02-25 Abbott Gmbh & Co Kg Verfahren zur schonenden herstellung hochfeiner partikelsuspensionen und hochfeiner partikel sowie deren verwendung
DE102005053862A1 (de) * 2005-11-04 2007-05-10 Pharmasol Gmbh Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
EP2099420B8 (en) 2006-11-17 2017-03-15 PharmaSol GmbH Nanocrystals for use in topical cosmetic formulations and method of production thereof
DE102007001473A1 (de) 2007-01-08 2008-07-10 Andreas Lemke Verfahren zur Herstellung und Anwendung von Mikro- und/oder Nanosuspensionen durch aufbauende Mikronisierung in Gegenwart von Trockeneis und hohem Druck
US20080262078A1 (en) * 2007-04-20 2008-10-23 Namdeo Alok B Pharmaceutical Compositions
JP5161528B2 (ja) * 2007-10-02 2013-03-13 浜松ホトニクス株式会社 パクリタキセル微粒子、パクリタキセル微粒子分散液、および、これらの製造方法
JP5149585B2 (ja) * 2007-10-02 2013-02-20 浜松ホトニクス株式会社 微粒子分散液製造方法
US20090087460A1 (en) * 2007-10-02 2009-04-02 Hamamatsu Photonics K.K. Solid composition, microparticles, microparticle dispersion liquid, and manufacturing methods for these
CA2718416C (en) * 2008-03-13 2018-01-02 Mallinckrodt Inc. Multi-function, foot-activated controller for imaging system
HU230862B1 (hu) 2008-04-28 2018-10-29 DARHOLDING Vagyonkezelő Kft Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2011079232A1 (en) * 2009-12-23 2011-06-30 Psivida Us, Inc. Sustained release delivery devices
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
EP2583672A1 (en) 2011-10-17 2013-04-24 PharmaSol GmbH Nanocrystals and amorphous nanoparticles and method for production of the same by a low energy process
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
WO2020018974A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
EP3616688A1 (en) * 2018-08-27 2020-03-04 Centre National de la Recherche Scientifique - CNRS Preparation of nanosuspension comprising nanocrystals of active pharmaceutical ingredients with little or no stabilizing agents

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US107288A (en) * 1870-09-13 Improvement in thread-spools
DE738604C (de) * 1935-07-09 1943-08-23 Rudolf Degkwitz Dr Verfahren zur Herstellung von Hydrosolen mit waehlbarer Gestalt und waehlbarer Groesse der kolloiden Teilchen
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
DE2362785A1 (de) * 1973-12-18 1975-06-26 Atmos Fritzsching & Co Gmbh Verfahren zum haltbarmachen von kristallsuspensionen
FR2257266B1 (da) * 1974-01-10 1977-07-01 Pasteur Institut
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
CA1098444A (en) * 1975-05-26 1981-03-31 Leo Geller Peptide preparations with prolonged action
US4117118A (en) * 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
IT1142172B (it) * 1978-10-19 1986-10-08 Sandoz Ag Nuovo impiego in terapeutica della ciclosporina-a e della diidrociclosporina-c
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4361580A (en) * 1980-06-20 1982-11-30 The Upjohn Manufacturing Company Aluminum ibuprofen pharmaceutical suspensions
IT1209276B (it) * 1980-11-05 1989-07-16 Magis Farmaceutici Composizione farmaceutica per la somministrazione orale del metilestere dell'acido 13a-etil-2,3,5,6,12,13,13a,13b-ottaidro-12-idrossi1h-indolo-[3,2,1-de] pirido [3,2,1-ij] [1,5] naftiridina -12-carbossilico
PH20649A (en) * 1981-09-22 1987-03-16 Gist Brocades Nv Bismuth containing composition and method for the preparation thereof
GB8322364D0 (en) * 1983-08-19 1983-09-21 May & Baker Ltd Compositions of matter
CA1239349A (en) * 1983-10-10 1988-07-19 Eberhard F. Gottwald Pharmaceutical composition containing cimetidine
EP0138216B1 (en) * 1983-10-14 1993-01-07 Sumitomo Pharmaceuticals Company, Limited Sustained-release ifn preparation for parenteral administration
JPS60139688A (ja) * 1983-12-28 1985-07-24 Tokyo Tanabe Co Ltd 無定形ジヒドロピリジン粉末製剤
DE3347579A1 (de) * 1983-12-30 1985-07-11 Hoechst Ag, 6230 Frankfurt Zubereitungen schwer wasserloeslicher anthelminthika und verfahren zu ihrer herstellung
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
DE3515335C2 (de) * 1985-04-27 1995-01-26 Bayer Ag Arzneizubereitung enthaltend Dihydropyridine und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
IL84855A (en) 1992-03-29
ATA333087A (de) 1993-12-15
AU8282887A (en) 1988-06-23
IT1230118B (it) 1991-10-07
NL194638B (nl) 2002-06-03
ES2028492A6 (es) 1992-07-01
DE3742473A1 (de) 1988-07-28
GR871938B (en) 1988-04-05
IE61179B1 (en) 1994-10-05
AU606908B2 (en) 1991-02-21
US5389382A (en) 1995-02-14
LU87079A1 (fr) 1988-07-14
NL194638C (nl) 2002-10-04
IE873425L (en) 1988-06-19
CA1308656C (en) 1992-10-13
DK664187D0 (da) 1987-12-17
DK173319B1 (da) 2000-07-24
SE503020C2 (sv) 1996-03-11
KR880007061A (ko) 1988-08-26
CH679451A5 (da) 1992-02-28
NL8702998A (nl) 1988-07-18
BE1000848A3 (fr) 1989-04-18
SE8705043L (sv) 1988-06-20
SE8705043D0 (sv) 1987-12-17
GB2200048A (en) 1988-07-27
FR2608427A1 (fr) 1988-06-24
KR960005136B1 (ko) 1996-04-22
DK664187A (da) 1988-06-20
AT397914B (de) 1994-08-25
PT86399B (pt) 1994-10-31
DK173345B1 (da) 2000-08-07
HU205861B (en) 1992-07-28
PT86399A (pt) 1989-01-17
FR2608427B1 (fr) 1991-02-08
ZA879533B (en) 1989-08-30
MY102037A (en) 1992-02-29
NZ222964A (en) 1991-01-29
DE3742473C2 (de) 1998-11-19
JPS63165312A (ja) 1988-07-08
GB2200048B (en) 1991-02-06
DD281344A5 (de) 1990-08-08
JP2617958B2 (ja) 1997-06-11
IL84855A0 (en) 1988-06-30
IT8748729A0 (it) 1987-12-18
HUT52941A (en) 1990-09-28
GB8729404D0 (en) 1988-02-03

Similar Documents

Publication Publication Date Title
DK200000266A (da) Farmaceutisk sammensætning indeholdende en opløsning af cyclosporin.
ATE77946T1 (de) Injizierbares langwirkendes mikroteilchenpr|parat zur verabreichung entzuendungshemmender mittel.
EP0167825A3 (en) Lipid nano pellets as drug carriers for oral administration
CA2055594A1 (en) Percutaneous lymphography
DE69511539T2 (de) Eine cyclosporin enthaltende zubereitung und ein verfahren für ihre herstellung
UA27698C2 (uk) Спосіб одержання мікрокапсули поліпептиду
FI852995A0 (fi) Stabila salter av polyanioner innehaollande s-adenosyl-l-methionin (sam).
EP0347598A3 (en) Polyphenylene ether/rubber modified polystyrene composition suitable for blow molding large parts
BG101443A (en) Cyclosporine compositions for oral administration
Wlodawer et al. Morphological changes in isolated rat-liver mitochondria during swelling and contraction
JPS5716818A (en) Steroid fatty emulsion
Rong-Kun et al. The effect of various polymeric coating systems on the dissolution and tableting properties of potassium chloride microcapsules
ES8204279A1 (es) Procedimiento de modificacion artificial de las precipitaciones atmosfericos,.
Pfeifer et al. Stimulation of cellular autophagy by parathyroid hormone and cyclic adenosine 3′, 5′: Monophosphate in isolated tubular fragments from the rat’s kidney cortex
DK0946149T3 (da) Homogene præformuleringer indeholdende steroider i høj koncentration til fremstilling af lavdoserede faste og halvfaste farmaceutiske præparater
EP0129947A3 (en) Contraceptive compositions based on esters of levo-norgestrel
GB2130588B (en) Micronised 2a-cyano-4a,5a-epoxy-3-oxo steroids
Yukitake et al. Ultrastructural studies on the secretory cycle of the neurosecretory cells and the formation of Herring bodies in the paraventricular nucleus of the rat
Tasaka et al. Histamine release induced by histone and related morphological changes in mast cells
JPS56127307A (en) Blood-coagulation factor 8 pharmaceutical for oral administration
KR830004206A (ko) 이소류우신의 정제방법
Costa et al. Hydrogen effects in beta-titanium alloys
Salama et al. Norepinephrine turnover and brain monoamine levels in septal lesioned aggressive rats
Reichard et al. Adrenal influences on distribution of injected colloidal thorium
Oberling et al. Autophagia in Myeloid Precursors: An Explanation for Neutropenia in Chediak‐Higashi Syndrome?

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired